Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer

Journal of Endocrinological Investigation

Volumn 20, Issue 9, 1997, Pages 566-568

  Reznik, Y ^a,c   Chapon, F ^a   Lahlou, N ^b   Deboucher, N ^a   Mahoudeau, J ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b INSERM   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

GnRH agonist; Gonadotroph adenoma; Pituitary apoplexy; Prostatic cancer

Indexed keywords

FOLLITROPIN; GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ARTICLE; CASE REPORT; FOLLITROPIN RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS APOPLEXY; IMAGING; IMMUNOCYTOCHEMISTRY; INTRACRANIAL HYPERTENSION; LUTEINIZING HORMONE RELEASE; MALE; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

EID: 0031456235     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03348020     Document Type: Article

References (13)

1. Kuhn J.M.,Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J.F., Costa P., Husson J.M., Dahan R., Bertagna C., Edelstein R. Prevention of the transient adverse effects of a gonadotrophin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. 321:413, 1989.
2. Kwekkeboom D.J., de Jong F.H. Lamberts S.W.J. Gonadotrophin release by clinically nonfunctioning and gonadotroph pituitary adenomas in vivo and in vitro: relation to sex and effects of thyrotropin-releasing hormone, gonadotrophin-releasing hormone, and bromocriptine. J. Clin. Endocrinol. Metab. 68: 1128, 1989.
3. Daneshdoost L., Gennarelli T.A., Bashey H.M., Savino P.J., Sergott B.C., Bosley T.M. Snyder P.J. Recognition of gonadotroph adenomas in women. N. Engl. J. Med. 324: 589, 1991.
4. Sassolas G., Lejeune H., Trouillas J., Forest M.G., Claustrat B., Lahlou N., Loras B. Gonadotrophin-releasing hormone agonists are unsuccessful in reducing tumoural gonadotrophin secretion in two patients with gonadotrophin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 67: 180; 1988.
5. Klibanski A., Jameson J.L., Biller B.M.K., Crowley W.F., Zervas N.T., Rivier J., Vale W.W., Bikkal H. Gonadotrophin and alpha-subunit responses to chronic gonadotrophin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumours. J. Clin. Endocrinol. Metab. 68: 81, 1989.
6. Chanson P., Lahlou N., Warnet A., Roger M., Sassolas G., Lubetzki J., Schaison G., Bouchard P. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas. J. Endocrinol. Invest. 17:91, 1994.
7. Labat-Moleur F., Trouillas J., Seret-Begue D., Kujas M., Delisle M.B.,Ronin C. Evaluation of 29 monoclonal and polyclonal antibodies used in the diagnosis of pituitary adenomas. Pathol. Res. Pract. 187:534, 1991.
8. Korsic M., Lelas-Bahun N., Surdonja P., Besenski N., Horvat S., Plavsic V. Infarction of FSH-secreting pituitary adenoma. Acta Endocrinol. (Copenh.) 107: 149, 1984.
9. Arafah B.M., Taylor H.C., Salazar R., Saadi H., Selman W.R. Apoplexy of a pituitary adenoma after dynamic testing with gonadotrophin-releasing hormone. Am. J. Med. 87: 103, 1989.
10. Masson E.A., Atkin S.L., Diver M., White M.C. Pituitary apoplexy and sudden blindness following the administration of gonadotrophin releasing hormone. Clin. Endocrinol. (Oxf.) 38: 109, 1993.
11. Chanson P., Schaison G. Pituitary apoplexy caused by GnRH-agonist treatment revealing gonadotroph adenoma. J. Clin. Endocrinol. Metab. 80: 2267, 1995.
12. Ando S., Hoshino T., Mihara S. Pituitary apoplexy after goserelin. Lancet 345: 458, 1995.
13. Schuval B.J., Kirschenbaum A., Wolfe D., Post K.D., Levine A. Lack of effect of a gonadotropin-releasing hormone agonist in a patient with prostate cancer and a gonadotroph adenoma. J. Clin. Endocrinol. Metab 87: 864, 1996.